Ipca Laboratories (NSE: IPCALAB) is a leading pharmaceutical company in India that produces and markets a broad range of prescription and non-prescription drugs, APIs (Active Pharmaceutical Ingredients), and intermediates. The company was founded in 1949 and is headquartered in Mumbai, India. It has a global presence with operations in over 120 countries.
The company has a strong product portfolio that includes anti-malarial, anti-emetic, anti-inflammatory, cardiovascular, anti-diabetic, anti-depressant, and anti-bacterial drugs. Some of its well-known brands include Aralen, Hydroxychloroquine Sulphate, Azithral, and Lariago. In terms of earnings, Revenue from Operations for Q3 FY23 was ₹1,546 crore, a 8% increase from ₹1,430.47 crore in the same period last year. The third quarter’s other income, which contributed ₹30.89 Crore to the Total Revenue. Meanwhile, the Profit Before Tax improved to ₹169.34 Crore from ₹260.66 Crore from the same quarter previous year. The Consolidated Net Profit was ₹107.84 crore, down 45% from ₹196.96 crore in the same quarter last year. This quarter’s earnings per share was ₹4.25.